Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan

References

• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822–30.
   PubMed Web of Science ®Google Scholar
• Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–83.
   PubMed Web of Science ®Google Scholar
• Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69(1):86–90.
   PubMed Web of Science ®Google Scholar
• Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20(6):636–47.
   PubMedGoogle Scholar
• Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276–80.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4(1):16–21.
   PubMed Web of Science ®Google Scholar
• Reddy D, Mitsuyasu R. HIV-associated multicentric Castleman disease. Curr Opin Oncol. 2011;23(5):475–81.
   PubMed Web of Science ®Google Scholar
• Robinson D Jr, Reynolds M, Casper C, Dispenzieri A, Vermeulen J, Payne K, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol. 2014;165(1):39–48.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7(3):211–31.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3(9):1202–16.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, et al. Clinical features and treatment of multicentric castleman's disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematopathol. 2013;53(1):69–77.
   PubMedGoogle Scholar
• Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–75.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–57.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, et al. Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan. Modern Rheumatol. 2018;28(1):161–7.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21(4):266–78.
   PubMed Web of Science ®Google Scholar
• Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989;86(19):7547–51.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheumatic Dis. 2000;59(90001): i21–7.
   PubMedGoogle Scholar
• Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 2002;20(6):304–11.
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74(4):1360–7.
   PubMed Web of Science ®Google Scholar
• Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves Sylvant for rare Castleman's disease. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125496Orig1s000TOC.cfm.
   Google Scholar
• Product monograph for SYLVANT. Health Canada; 2014. Available from: https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00193.
   Google Scholar
• European Commission. Community register of medicinal products for human use: SYLVANT authorisation. 2014. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant.
   Google Scholar
• van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol. 2012;87(11):997–1002.
   PubMed Web of Science ®Google Scholar
• Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematopathol. 2013;53(1):79–85.
   PubMedGoogle Scholar
• Johkoh T, Muller NL, Ichikado K, Nishimoto N, Yoshizaki K, Honda O, et al. Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology. 1998;209(2):477–81.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, et al. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci. 2010;25(9):1364–7.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.
   PubMed Web of Science ®Google Scholar
• American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
   PubMedGoogle Scholar
• Travis WD, Costabel U, Hansell DM, King TE, Jr., Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
   PubMed Web of Science ®Google Scholar
• Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol. 2015;84(3):542–6.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206–16.
   PubMed Web of Science ®Google Scholar
• Scarpioni R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol. 2016;5(1):66–75.
   PubMedGoogle Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–9.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Oka S, Shimada K, Tsuchiya N, Tohma S. Genetics of interstitial lung disease: Vol de Nuit (Night Flight). Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):1–7.
   PubMedGoogle Scholar
• Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–7.
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999;105(4):360–6.
   PubMed Web of Science ®Google Scholar
• Man L, Goudar RK. Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease. Eur J Haematol. 2013;91(3):273–6.
   PubMed Web of Science ®Google Scholar
• Kanda J, Kawabata H, Yamaji Y, Ichinohe T, Ishikawa T, Tamura T, et al. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol. 2007;85(3):207–11.
   PubMed Web of Science ®Google Scholar
• Arita Y, Sakata Y, Sudo T, Maeda T, Matsuoka K, Tamai K, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels. 2010;25(5):444–7.
   PubMed Web of Science ®Google Scholar
• Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316–24.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Japanese Government Statistics. Trends in mean height, body weight and body mass index in 2012.
   Google Scholar